Dr. Mark Kirchhof

Dermatologist, Ottawa, ON

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 65 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

12:45 PM - 1:45 PM LEO Pharma Open Session

Friday NOV 12, 2021

Uncovering: Novel Agents, Key Data, and Patient Confidence in AD


This session is a dynamic and interactive program designed to uncover the clinical benefits of novel AD treatments, reveal key data for efficacy outcomes, and includes an interactive discussion on practical applications.

 

Objectives:

At the end of this program, participants will be able to:

  1. Define the clinical benefits of novel therapies
  2. Apply key data for effective outcomes with AD patients
  3. Explain to patients the mechanism of effect of AD therapy to support body and emotional confidence
11:10 AM - 11:40 AM Amgen Canada Inc Open Presentation

Saturday NOV 13, 2021

What's new in Hidradenitis Suppurativa: From B cells to Biosimilars


Hidradenitis Suppurativa (HS) is a chronic relapsing inflammatory condition that has a major impact on patient's lives. New discoveries about the pathogenesis of HS continue to inform treatment options for these patients. The number of therapeutic options is increasing and many patients are now benefiting from immunomodulatory therapies. Clinicians need to be up to date with the most recent advancements in HS to provide the best therapeutic options for their patients.

Objectives:

  • Review new findings on the pathogenesis of HS
  • Explore therapeutic options for HS
  • Summarize recent important clinically relevant studies